Use of statins and the risk of death in patients with prostate cancer.
暂无分享,去创建一个
G. Batist | S. Suissa | A. Aprikian | S. Benayoun | O. Yu | M. Eberg | L. Azoulay
[1] J. Stanford,et al. Statin Use in Relation to Prostate Cancer Outcomes in a Population‐based Patient Cohort Study , 2013, The Prostate.
[2] S. Daneshmand,et al. Androgen deprivation therapy: evidence‐based management of side effects , 2013, BJU international.
[3] E. Kopel,et al. Statin use and reduced cancer-related mortality. , 2013, The New England journal of medicine.
[4] S. Marcella,et al. Statin use and fatal prostate cancer , 2012, Cancer.
[5] N. Clarke,et al. The differential effects of statins on the metastatic behaviour of prostate cancer , 2012, British Journal of Cancer.
[6] Leonard W. D'Avolio,et al. Statins and prostate cancer diagnosis and grade in a veterans population. , 2011, Journal of the National Cancer Institute.
[7] Y. Yamada,et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. , 2011, International journal of radiation oncology, biology, physics.
[8] A. D'Amico,et al. Association of statin and nonsteroidal anti‐inflammatory drug use with prostate cancer outcomes: results from CaPSURE , 2010, BJU international.
[9] J. S. St. Sauver,et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. , 2010, The Journal of urology.
[10] M. Terris,et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy , 2010, Cancer.
[11] R. Weichselbaum,et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] James M Wright,et al. Statin Adherence and Risk of Accidents: A Cautionary Tale , 2009, Circulation.
[13] W. Catalona,et al. IS STATIN USE ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS , 2009 .
[14] H. Sandler,et al. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. , 2009, Urology.
[15] Ping K Ruan,et al. Analyses of cumulative incidence functions via non‐parametric multiple imputation , 2008, Statistics in medicine.
[16] S. Basaria,et al. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. , 2008, The Journal of clinical endocrinology and metabolism.
[17] S. Suissa. Practice of Epidemiology Immortal Time Bias in Pharmacoepidemiology , 2008 .
[18] E. Rimm,et al. Statin drugs and risk of advanced prostate cancer. , 2006, Journal of the National Cancer Institute.
[19] K. Wallner,et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. , 2005, Urology.
[20] M. Freeman,et al. Cholesterol and prostate cancer , 2004, Journal of cellular biochemistry.
[21] P. Nelson,et al. Determining cause of death in prostate cancer: are death certificates valid? , 2001, Journal of the National Cancer Institute.
[22] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[23] D. Eisenberg,et al. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. , 1998, The American journal of medicine.